Curis (CRIS +2.2%) initiates a Phase 1 dose-escalation study of the oral, synthetic, small...

|By:, SA News Editor

Curis (CRIS +2.2%) initiates a Phase 1 dose-escalation study of the oral, synthetic, small molecule CUDC-427 in patients with advanced and refractory solid tumors or lymphoma. The company says the trial "builds on the single agent clinical results observed in the initial Phase 1 trial of CUDC-427, which were presented at ASCO." It's worth noting that the stock fell sharply from June 3-June 5 following the company's ASCO presentation.

Subscribe for full text news in your inbox